Predictive Oncology (NASDAQ:POAI) Stock Crosses Below 200 Day Moving Average – Time to Sell?

Predictive Oncology Inc. (NASDAQ:POAI)’s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $10.47 and traded as low as $6.52. Predictive Oncology shares last traded at $6.7596, with a volume of 40,332 shares.

Analyst Upgrades and Downgrades

Several research firms have recently commented on POAI. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Predictive Oncology in a report on Wednesday, October 8th. Wall Street Zen cut shares of Predictive Oncology to a “strong sell” rating in a report on Saturday, December 6th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Predictive Oncology Price Performance

The firm’s fifty day moving average price is $6.22 and its 200-day moving average price is $10.47. The company has a market cap of $22.94 million, a price-to-earnings ratio of -0.50 and a beta of 1.35.

Predictive Oncology (NASDAQ:POAI) last issued its quarterly earnings data on Friday, November 14th. The medical instruments supplier reported ($4.52) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($3.17). The firm had revenue of $0.00 million during the quarter, compared to the consensus estimate of $1.50 million. Predictive Oncology had a negative net margin of 5,065.23% and a negative return on equity of 732.73%. As a group, equities analysts forecast that Predictive Oncology Inc. will post -2.08 earnings per share for the current fiscal year.

Predictive Oncology Company Profile

Predictive Oncology, Inc is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines.

The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells.